Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.60 |
| ▸ | KHK | P50053 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.45 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.45 |
| ▸ | BPTF | Q12830 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 1/20 | 0.43 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6488653 | 1.00 | NOTUM (0.60) | NOTUMKHKADRB1DPP4KCNH2 | |
| SCHEMBL1349699 | 1.00 | NOTUM (0.60) | NOTUMKHKADRB1DPP4KCNH2 | |
| Oxalic Acid SCHEMBL9310666 | 0.91 | NOTUM (0.67) | NOTUMKHKADRB1DPP4GPR119 | |
| SCHEMBL9312444 | 0.90 | NOTUM (0.54) | NOTUMKHKADRB1DPP4KCNH2 | |
| SCHEMBL9982790 | 0.90 | ADRB1 (0.59) | NOTUMADRB1DPP4KCNH2GPR119 | |
| Hydrochloric Acid SCHEMBL9876690 | 0.87 | ADRB1 (0.56) | NOTUMKHKADRB1DPP4KCNH2 | |
| SCHEMBL16785627 | 0.85 | NOTUM (0.61) | NOTUMADRB1DPP4KCNH2GPR119 | |
| SCHEMBL16785618 | 0.85 | NOTUM (0.61) | NOTUMADRB1DPP4KCNH2GPR119 | |
| SCHEMBL12653838 | 0.85 | NOTUM (0.61) | NOTUMADRB1DPP4KCNH2GPR119 | |
| SCHEMBL8038976 | 0.81 | DPP4 (0.55) | KHKADRB1DPP4KCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063078-B2 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | GLAXOSMITHKLINE LLC (US) | 2011-11-22 | — | — | US | disclosed |
| EP-2298757-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | SMITHKLINE BEECHAM PLC. (GB) | 2009-06-25 | — | — | US | disclosed |
| EP-1425277-B8 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | GLAXO GROUP LTD (GB) | 2009-04-01 | — | — | EP | disclosed |
| EP-2036902-A2 | Urea compounds active as vanilloid receptor antagonist for the treatment of pain | Glaxo Group Limited (GB) | 2009-03-18 | — | — | EP | disclosed |
| US-6939891-B2 | Nitrogen compounds such as N-(4-Fluorophenyl)-N'-[(R)-1-((3-methylphenyl)pyrrolidin-2-ylmethyl)]urea, used as analgesics | SMITHKLINE BEECHAM, PLC (GB) | 2005-09-06 | — | — | US | disclosed |
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1425277-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SmithKline Beecham P.L.C. (GB) | 2004-06-09 | — | — | EP | disclosed |
| EP-1392651-A1 | HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-03 | — | — | EP | disclosed |
| WO-2003022809-A2 | UREA-COMPOUNDS ACTIVE AS VANILLOID RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PAIN | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-03-20 | — | — | WO | disclosed |
| WO-2002090326-A1 | HETEROCYCLIC UREAS, THEIR PREPARATION AND THEIR USE AS VANILLOID RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163506-A1 | Urea-compounds active as vanilloid receptor antagonists for the treatment of pain | TRPV1, OPRL1, UTS2R | NOTUM 2509/4885KHK 2931/4885ADRB1 124/4885 |
| US-20040171639-A1 | Heterocyclic ureas, their preparation and their use as vanilloid receptor antagonists | TRPV1, UTS2R, GPR17 | NOTUM 3348/4885KHK 2636/4885ADRB1 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.